Literature DB >> 19389631

Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands.

John David Norris1, James David Joseph, Andrea Barreto Sherk, Dalia Juzumiene, Philip Stewart Turnbull, Stephen William Rafferty, Huaxia Cui, Erin Anderson, Daju Fan, Delita Arnelle Dye, Xiang Deng, Dmitri Kazmin, Ching-Yi Chang, Timothy Mark Willson, Donald Patrick McDonnell.   

Abstract

The pharmacological activity of different nuclear receptor ligands is reflected by their impact on receptor structure. Thus, we asked whether differential presentation of protein-protein interaction surfaces on the androgen receptor (AR), a surrogate assay of receptor conformation, could be used in a prospective manner to define the pharmacological activity of bound ligands. To this end, we identified over 150 proteins/polypeptides whose ability to interact with AR is influenced in a differential manner by ligand binding. The most discriminatory of these protein-AR interactions were used to develop a robust compound-profiling tool that enabled the separation of ligands into functionally distinguishable classes. Importantly, the ligands within each class exhibited similar pharmacological activities, a result that highlights the relationship between receptor structure and activity and provides direction for the discovery of novel AR modulators.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19389631      PMCID: PMC2673463          DOI: 10.1016/j.chembiol.2009.01.016

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  50 in total

1.  Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations.

Authors:  P M Matias; P Donner; R Coelho; M Thomaz; C Peixoto; S Macedo; N Otto; S Joschko; P Scholz; A Wegg; S Bäsler; M Schäfer; U Egner; M A Carrondo
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

2.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  JAMA       Date:  2006-06-05       Impact factor: 56.272

3.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors.

Authors:  D M Heery; E Kalkhoven; S Hoare; M G Parker
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

4.  Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor.

Authors:  J W Lee; H S Choi; J Gyuris; R Brent; D D Moore
Journal:  Mol Endocrinol       Date:  1995-02

5.  Analysis of androgen receptor-DNA interactions with receptor proteins produced in insect cells.

Authors:  P J Kallio; J J Palvimo; M Mehto; O A Jänne
Journal:  J Biol Chem       Date:  1994-04-15       Impact factor: 5.157

6.  FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor.

Authors:  B He; J A Kemppainen; E M Wilson
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

7.  Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice.

Authors:  K A Klein; R E Reiter; J Redula; H Moradi; X L Zhu; A R Brothman; D J Lamb; M Marcelli; A Belldegrun; O N Witte; C L Sawyers
Journal:  Nat Med       Date:  1997-04       Impact factor: 53.440

8.  Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells.

Authors:  Hui-Kuan Lin; Yueh-Chiang Hu; Dong Kun Lee; Chawnshang Chang
Journal:  Mol Endocrinol       Date:  2004-06-17

9.  Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator.

Authors:  Kazuo Nishimura; Huei-Ju Ting; Yasunori Harada; Takashi Tokizane; Norio Nonomura; Hong-Yo Kang; Hong-Chiang Chang; Shuyuan Yeh; Hiroshi Miyamoto; Masaru Shin; Katsuyuki Aozasa; Akihiko Okuyama; Chawnshang Chang
Journal:  Cancer Res       Date:  2003-08-15       Impact factor: 12.701

10.  A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression.

Authors:  Qianben Wang; Dipali Sharma; Yunsheng Ren; Joseph D Fondell
Journal:  J Biol Chem       Date:  2002-09-05       Impact factor: 5.157

View more
  33 in total

1.  Identical gene regulation patterns of T3 and selective thyroid hormone receptor modulator GC-1.

Authors:  Chaoshen Yuan; Jean Z H Lin; Douglas H Sieglaff; Steven D Ayers; Frances Denoto-Reynolds; John D Baxter; Paul Webb
Journal:  Endocrinology       Date:  2011-11-08       Impact factor: 4.736

Review 2.  Minireview: dynamic structures of nuclear hormone receptors: new promises and challenges.

Authors:  S Stoney Simons; Dean P Edwards; Raj Kumar
Journal:  Mol Endocrinol       Date:  2013-11-27

3.  ELF3 is a repressor of androgen receptor action in prostate cancer cells.

Authors:  A Shatnawi; J D Norris; C Chaveroux; J S Jasper; A B Sherk; D P McDonnell; V Giguère
Journal:  Oncogene       Date:  2013-02-25       Impact factor: 9.867

4.  Safety, pharmacokinetics and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women.

Authors:  Richard V Clark; Ann C Walker; Susan Andrews; Philip Turnbull; Jeffrey A Wald; Mindy H Magee
Journal:  Br J Clin Pharmacol       Date:  2017-06-10       Impact factor: 4.335

Review 5.  New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2.

Authors:  Terry Kenakin
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

Review 6.  The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer.

Authors:  Erik R Nelson
Journal:  Mol Cell Endocrinol       Date:  2017-09-15       Impact factor: 4.102

Review 7.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

Review 8.  Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors.

Authors:  William Hankey; Zhong Chen; Qianben Wang
Journal:  Cancer Res       Date:  2020-02-24       Impact factor: 12.701

Review 9.  Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs).

Authors:  Terry W Moore; Christopher G Mayne; John A Katzenellenbogen
Journal:  Mol Endocrinol       Date:  2009-11-20

10.  Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities.

Authors:  Barbara J Attardi; Stephanie T Page; Sheri A Hild; Christopher C Coss; Alvin M Matsumoto
Journal:  J Steroid Biochem Mol Biol       Date:  2009-11-24       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.